Sigma Healthcare (ASX:SIG): What Does Its October Trading Update Reveal About Pharmacy Sales?

Aditi Sarkar

27 October 2026 10:29 PM AEDT

Sigma Healthcare (ASX:SIG): What Does Its October Trading Update Reveal About Pharmacy Sales?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Sigma Healthcare (ASX:SIG) reported FY26 revenue of AUD 10.835bn, up 15.5% against pro-forma FY25.
FY26 normalised EBIT increased 20.6% to AUD 1.09bn; normalised NPAT reached AUD 732.3mn.
Australian Chemist Warehouse branded-store sales grew 12.1% from 1 July to 16 October 2026.
International branded-store sales rose 30.2% in constant currency in the September quarter.

Sigma Healthcare Limited (ASX:SIG) operates pharmaceutical wholesaling and pharmacy franchise businesses, including the Chemist Warehouse, Amcal and Discount Drug Stores networks. Its October trading update follows a financial year of expanded network sales and merger integration activity. Sigma Healthcare (ASX:SIG) was quoted at AUD 2.73 for 27 October 2026. The latest disclosures distinguish ongoing demand in health-related categories from softer spending in some discretionary products, while outlining planned store additions and distribution efficiencies.

Company Business

Sigma Healthcare (ASX:SIG) combines pharmacy franchising, retail network services and pharmaceutical distribution. Chemist Warehouse branded outlets sell prescription medicines, over-the-counter products, beauty items and personal care goods. The company also supports the Amcal and Discount Drug Stores brands and supplies pharmacies through a distribution network across Australia. Its operations encompass domestic wholesale customers as well as international Chemist Warehouse activities, including New Zealand and Ireland.

The business earns income through distribution and retail-related arrangements rather than depending on a single product category. Its operating performance reflects store-network expansion, customer sales, pharmaceutical dispensing activity, buying terms and warehouse efficiency. The merger with Chemist Warehouse created a larger operating platform, with management pursuing technology, procurement and distribution integration during FY27.

Recent Development

At its annual general meeting in October 2026, Sigma Healthcare (ASX:SIG) reported that Australian Chemist Warehouse branded-store sales grew 12.1% between 1 July and 16 October 2026. Like-for-like sales rose 9.8% over the same period. For international stores, sales increased 30.2% in constant currency during the three months ended 30 September 2026, while like-for-like growth was 15.8%. These figures describe different reporting windows and should not be treated as directly comparable periods.

Management identified softer purchasing in ladies’ fragrances, vitamins and supplements amid cost-of-living pressures, contrasting with demand in beauty, healthcare and products associated with GLP-1 medicines. It also indicated plans to onboard 14 Chemist Warehouse stores, 42 Amcal and Discount Drug Stores, and 19 international stores during H1 FY27. These are stated onboarding plans, not completed openings.

Financial Performance and Sector Context

For the year ended 30 June 2026, Sigma Healthcare (ASX:SIG) reported revenue of AUD 10,835.0mn, an increase of 15.5% against the normalised pro-forma FY25 comparison of AUD 9,380.1mn. Normalised EBIT rose 20.6% to AUD 1,090.0mn from AUD 903.4mn, with its margin increasing from 9.63% to 10.06%. Normalised NPAT increased 22.3% to AUD 732.3mn, compared with AUD 598.8mn. These normalised comparisons account for the merged business on a pro-forma basis.

Australian segment revenue reached AUD 10,413.6mn, up 14.9%, while normalised EBIT rose 18.3% to AUD 1,034.2mn. International revenue increased 33.0% to AUD 421.4mn and normalised EBIT advanced 91.3% to AUD 55.8mn. The company reported statutory NPAT of AUD 708.7mn, below normalised NPAT, reflecting adjustments including merger-related and integration costs.

Net debt was AUD 663.2mn at year-end, equivalent to 0.57 times normalised EBITDA. Sigma reported AUD 32.6mn of FY26 integration synergies and retained its target of AUD 100mn in annual synergies during FY29. It declared a fully franked final dividend of AUD 0.02 per share, in addition to an AUD 0.02 interim dividend. Pharmacy-sector conditions remain affected by consumer spending, dispensing volumes, reimbursement arrangements and distribution operating costs.

Risks to Consider

Sigma Healthcare (ASX:SIG) faces execution risks in integrating distribution centres, information systems and supplier arrangements. Planned store openings and network refurbishment depend on available premises, franchisee participation and operating readiness. Consumer cost pressures can affect discretionary pharmacy categories, while international expansion introduces additional operating and regulatory complexity. Synergy delivery may also require one-off expenditure before targeted savings appear in earnings.

What to Watch Next

Investors following Sigma Healthcare (ASX:SIG) can monitor the completion of proposed H1 FY27 store additions, Australian like-for-like sales, international trading and changes in category demand. Other relevant measures include progress towards the FY29 annual synergy target, distribution consolidation and net debt. The next reporting updates should clarify whether sales expansion continues to exceed underlying operating-cost increases.

Key Insights

Sigma Healthcare (ASX:SIG) reported higher FY26 revenue and normalised earnings, with October trading figures showing sales increases in Australian and international Chemist Warehouse networks. The latest update also identifies uneven demand between discretionary and health-related categories. Store onboarding, integration savings, distribution costs and cash generation remain measurable factors for subsequent reporting periods.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.